A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab
(MPDL3280A) in combination with carboplatin and paclitaxel with or without bevacizumab
compared with treatment with carboplatin plus (+) paclitaxel and bevacizumab in
chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society